Claims for Patent: 8,367,069

Summary for Patent: 8,367,069

Title:	Cytotoxic T cell defined EGFR peptide and an optimized derivative peptide
Abstract:	The invention provides a polypeptide having a sequence of amino acids consisting of IXDFGLAKL (SEQ ID NO: 1), as well as a nucleic acid encoding the polypeptide, vector comprising the nucleic acid, cell comprising the vector, and compositions thereof. The invention also provides a method of inducing a T-cell response in a patient with epithelial cancer, and a method inhibiting epithelial cancer, wherein the methods comprise administering the composition of the invention. The invention further provides a method of stimulating a cell with the inventive polypeptide and a cell so stimulated.
Inventor(s):	Ferris; Robert L. (Pittsburgh, PA), Andrade; Pedro (Pittsburgh, PA), Lopez-Albaitero; Andres (Pittsburgh, PA)
Assignee:	University of Pittsburgh--of the Commonwealth System of Higher Education (Pittsburgh, PA)
Application Number:	12/959,073
Patent Claims:	1. An isolated or substantially purified polypeptide consisting of (SEQ ID NO: 1). 2. A composition comprising a polypeptide consisting of SEQ ID NO: 1 and a carrier. 3. The composition of claim 2, further comprising an adjuvant. 4. The composition of claim 3, wherein the adjuvant is selected from the group consisting of IL-1-beta, IL-2, IL-4, IL-6, IL-7, IL-12, IL-15, IL-21, PGE, RANTES, GM-CSF, TNF-alpha, IFN-gamma, incomplete Freund's adjuvant, alum, aluminum salts, aluminum phosphate, aluminum hydroxide, aluminum silica, Montanide, calcium phosphate, and combinations thereof. 5. The composition of claim 2, further comprising a chemotherapeutic agent. 6. The composition of claim 5, wherein the chemotherapeutic agent is an EGFR family-specific antibody. 7. The composition of claim 6, wherein the EGFR family-specific antibody is cetuximab. 8. The composition of claim 2, further comprising a tumor associated antigen selected from the group consisting of MAGE, p53, ErbB2, MUC-1, HAGE, and human papilloma virus. 9. The composition of claim 2, wherein the composition is a pharmaceutical composition and the carrier is a pharmaceutically acceptable carrier. 10. A method of inducing a cytotoxic T lymphocyte response in a patient with epithelial cancer cells expressing EGFR, comprising administering to the patient the composition of claim, such that a T cell cytotoxic T lymphocyte response against the epithelial cancer is induced.

Details for Patent 8,367,069

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2028-06-02
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2028-06-02